DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
Status:
Completed
Trial end date:
2021-06-10
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of itraconazole, a strong
inhibitor)of cytochrome P4503A , and phenytoin a strong inducer of cytochrome P450 3A,
CYP3A4, CYP1A2 and CYP2C19 on the pharmacokinetics of ASC41, a THR beta agonist tables in
healthy subjects. The PK, Safety and Tolerability of ASC 41 in Subjects with NAFLD will also
be evaluated. Approximately 24 subjects including 16 healthy volunteers (HVs) and 8 subjects
with NAFLD will be enrolled. This study consists of 3 cohorts.